Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Nilsine Partners LLC

Nilsine Partners LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,741 shares of the company’s stock after acquiring an additional 1,768 shares during the period. Nilsine Partners LLC’s holdings in Novo Nordisk A/S were worth $6,085,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NVO. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter worth about $28,000. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. Finally, M&R Capital Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after acquiring an additional 297 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the topic of several analyst reports. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Down 0.6 %

Shares of NVO stock opened at $87.45 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $392.43 billion, a P/E ratio of 28.30, a P/E/G ratio of 0.90 and a beta of 0.45. The firm has a 50-day moving average price of $95.35 and a 200 day moving average price of $114.80. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.